Zymeworks Licenses Experimental Lung Cancer Drug to Roche in Deal Worth Up to $813 Million
Roche gained global rights to develop and commercialize Zymeworks’ experimental lung cancer drug under a licensing deal worth up to $813 million.
Story updates
10:13:21 AM UTC
SquawkNews
Zymeworks entered into a Collaboration and License Agreement granting Roche exclusive worldwide rights to develop and commercialize ZW209 and other covered DLL3-targeting T-cell engagers. Roche will pay $55 million upfront after regulatory clearance, a $40 million milestone upon initiation of the f…
Zymeworks (NASDAQ: ZYME) said Friday that Roche (BX: RHO) has secured global rights to develop and commercialize its experimental lung cancer drug under a licensing agreement valued at up to $813 million.